The FDA has approved the fixed-dose combination of relatlimab plus nivolumab for the treatment of adult and pediatric patients who are 12 years of age or older and who have unresectable or metastatic melanoma.
The hair guru explains how he opened up the first dermatology practice dedicated to hair, pearls from his session, innovative therapies, and research he has recently submitted.
How will new federal law affect lives and wallets of physicians?
In 2023 as many as 11 biosimilars to Humira are headed for the US market.
Paller discusses her SPD 2024 lecture, "Updates from ISSVA, ESPD, and SID: What You Missed that Could Change Your Practice."
Delgocitinib is first-in-class pan-Janus kinase inhibitor.
Kirby presented at both Fall Clinical and the Inflammatory Disease Summit in Las Vegas.
The clinical and histologic subtypes encompassed by granulomatous dermatitis include palisaded neutrophilic granulomatous dermatitis and interstitial granulomatous dermatitis. This review compares the features of each cutaneous eruption.
Ami Greene, MD, discusses her beginner and intermediate SDPA fall conference sessions on dermoscopy.
Three distinct congresses known as RAVE (Revolutionizing Atopic Dermatitis, Alopecia Areata, and Vitiligo) will be held June 8-10, in Chicago, Illinois.
By integrating capabilities and services, we can create health experiences that are much more than the sum of their parts.
Joel Schlessinger, MD, shares his atopic dermatitis insights.
The clinical and histologic subtypes encompassed by granulomatous dermatitis include palisaded neutrophilic granulomatous dermatitis and interstitial granulomatous dermatitis. This review compares the features of each cutaneous eruption.
From explaining how medications work and should be taken to reviewing potential adverse effects and financial details, pharmacists are crucial resources for patients undergoing treatment for skin cancer.
Medical networks and smaller practices alike are facing spiraling inflation costs and staffing shortfalls due to waves of COVID cases that are impacting physicians, staff, and management.
Hyaluronic acid fillers and biostimulators were a couple of Prather's recent favorite aesthetic advancements.
Panelists discuss how health care providers must balance the convenience and accessibility of telemedicine with individual patient needs and clinical considerations when delivering dermatological care.
“I think some key things that stand out to me are that it's safe, effective, backed by rigorous clinical data, and has very high patient satisfaction,” Watchmaker said about the new product.
An expert in dermatology shares her thoughts at AAD on the sun protection needs in her patients with skin of color; highlighting the role of the Fitzpatrick skin type scale and compounds such as vitamin E and antioxidants.
Recent technological advancements such as the development and use of human cellular and tissue-based products and advanced skin substitutes have transformed limb preservation.
Closing out their discussion on the management of plaque psoriasis, panelists share their excitement for future directions in care.
In online discussion April 23, commissioners cited health care specifically among their reasons for supporting the ban.
New data from ADORING 1 and ADORING 2 show a rapid reduction in pruritus relief as early as 24 hours after the first application.
Nail psoriasis affects 50% of plaque psoriasis patients, making effective treatments crucial.
Erin Boh, MD, emphasizes the importance of patient empowerment and physician education surrounding the management of GPP.
Alexandra Kimball, MD, FAAD, reviews late-breaking data at AAD on lutikizumab for hidradenitis suppurativa.